
control study. Cancer Epidemiol Biomarkers Prev 2008; 17: 1723–30 doi: 10.1158/1055-9965.EPI-07-
2824 PMID: 18628424
4. Huo D, Adebamowo CA, Ogundiran TO, Akang EE, Campbell O, Adenipekun A, et al.: Parity and
breastfeeding are protective against breast cancer in Nigerian women. Br J Cancer 2008; 98: 992–6
doi: 10.1038/sj.bjc.6604275 PMID: 18301401
5. Turkoz FP, Solak M, Petekkaya I, Keskin O, Kertmen N, Sarici F, et al. Association between common
risk factors and molecular subtypes in breast cancer patients. Breast. 2013 Jun; 22(3):344–50 doi: 10.
1016/j.breast.2012.08.005 PMID: 22981738
6. Rakha EA, El-Sayed ME, Powe DG, Green AR, Habashy H, Grainge MJ, et al. Invasive lobular carci-
noma of the breast: response to hormonal therapy and outcomes.Eur J Cancer. 2008 Jan; 44(1):73–83
PMID: 18035533
7. Phipps AI, Malone KE, Porter PL, Daling JR, Li CI: Reproductive and hormonal risk factors for postmen-
opausal luminal, HER-2 overexpressing, and triple—negative breast cancer. Cancer 2008; 113: 1521–
6 doi: 10.1002/cncr.23786 PMID: 18726992
8. Yang L, Jacobsen KH. A systematic review of the association between breastfeeding and breast can-
cer. J Womens Health (Larchmt). 2008 Dec; 17(10):1635–45
9. Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN. Overview of resistance to systemic therapy
in patients with breast cancer. Adv Exp Med Biol. 2007; 608:1–22 PMID: 17993229
10. Travis RT, Reeves GK, Green J, Bull D, Tipper SJ, Baker K, Beral V, et al. Million Women Study Collab-
orators. Gene-environment interactions in 7610 women with breast cancer: prospective evidence from
the Million Women Study. Lancet. 2010; 375:2143–2151. doi: 10.1016/S0140-6736(10)60636-8 PMID:
20605201
11. Brouckaert O, Paridaens R, Floris G, Rakha E, Osborne K, Neven P. A critical review why assessment
of steroid hormone receptors in breast cancer should be quantitative. Ann Oncol. 2013 Jan; 24(1):47–
53. doi: 10.1093/annonc/mds238 Epub 2012 Jul 30 PMID: 22847811
12. Yerushalmi R, Woods R, Ravdin PM, et al. Ki67 in breast cancer: prognostic and predictive potential.
Lancet Oncol 2010; 11:174–183 doi: 10.1016/S1470-2045(09)70262-1 PMID: 20152769
13. Lyons TR, Schedin PJ, Borges VF. Pregnancy and breast cancer: when they collide. J Mammary
Gland Biol Neoplasia. 2009 Jun; 14(2):87–98 doi: 10.1007/s10911-009-9119-7 PMID: 19381788
14. Albrektsen G, Heuch I, Thoresen SØ: Histological type and grade of breast cancer tumors by parity,
age at birth, and time since birth: a register-based study in Norway. BMC Cancer. 2010, 10:226 doi: 10.
1186/1471-2407-10-226 PMID: 20492657
15. Sotgia F, Casimiro MC, Bonuccelli G, Liu M, Whitaker-Menezes D, Er O, et al. Loss of caveolin-3
induces a lactogenic microenvironment that is protective against mammary tumor formation. Am J
Pathol. 2009; 174(2):613–29. doi: 10.2353/ajpath.2009.080653 PMID: 19164602
16. Sotgia F, Del Galdo F, Casimiro MC, Bonuccelli G, Mercier I, Whitaker-Menezes D, et al. Caveolin-1 -/-
null mammary stromal fibroblast share characteristics with human breast cancer-associated fibroblasts.
Am J Pathol. 2009; 174(3):746–61. doi: 10.2353/ajpath.2009.080658 PMID: 19234134
17. Wiesner FG, Magener A, Fasching PA, Wesse J, Bani MR, Rauh C, et al. Ki-67 as a prognostic molecu-
lar marker in routine clinical use in breast cancer patients. Breast. 2009; 18:135–41 doi: 10.1016/j.
breast.2009.02.009 PMID: 19342238
18. Aleskandarany MA, Rakha EA, Macmillan RD, Powe DG, Ellis IO, Green AR. MIB1/Ki-67 labelling
index can classify grade 2 breast cancer into two clinically distinct subgroups. Breast Cancer Res
Treat. 2011; 127: 591–9 doi: 10.1007/s10549-010-1028-3 PMID: 20623333
19. Niikura N, Masuda S, Kumaki N, Xiaoyan T, Terada M, Terao M, et al. Prognostic significance of the
Ki67 scoring categories in breast cancer subgroups. Clin Breast Cancer. 2014 Oct; 14(5):323–329.e3
doi: 10.1016/j.clbc.2013.12.013 PMID: 24492237
20. Rossi L, Laas E, Mallon P, Vincent-Salomon A, Guinebretiere JM, et al. Prognostic impact of discrepant
Ki67 and mitotic index on hormone receptor-positive, HER2-negative breast carcinoma. Br J Cancer.
2015 Sep 29; 113(7):996–1002 doi: 10.1038/bjc.2015.239 PMID: 26379080
21. Engels CC, Fontein DB, Kuppen PJ, de Kruijf EM, Smit VT, Nortier JW, et al. Immunological subtypes
in breast cancer are prognostic for invasive ductal but not for invasive lobular breast carcinoma. Br J
Cancer. 2014 Jul 29; 111(3):532–8. doi: 10.1038/bjc.2014.338 PMID: 24937677
22. González-Sistal A, Baltasar-Sánchez A, Del Rio MC, Arias JI, Herranz M, Ruibal A. Association
Between Tumor Size and Immunohistochemical Expression of Ki-67, p53 and BCL2 in a Node-nega-
tive Breast Cancer Population Selected from a Breast Cancer Screening Program. Anticancer Res.
2014 Jan; 34(1):269–73. PMID: 24403473
Breastfeeding and Lobular Breast Carcinoma
PLOS ONE | DOI:10.1371/journal.pone.0151093 March 10, 2016 5/5